Rare catastrophes and evolutionary legacies: human germline gene variants in MLKL and the necroptosis signalling pathway

Sarah E. Garnish1,2 and Joanne M. Hildebrand1,2

1 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; 2 Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia

Correspondence: Joanne M. Hildebrand (jhildebrand@wehi.edu.au)

Programmed cell death has long been characterised as a key player in the development of human disease. Necroptosis is a lytic form of programmed cell death that is universally mediated by the effector protein mixed lineage kinase domain-like (MLKL), a pseudokinase. MLKL’s activating kinase, receptor interacting protein kinase 3 (RIPK3), is itself activated within context specific scaffolds of receptor interacting protein kinase 1 (RIPK1), Z-DNA Binding Protein-1 (ZBP1) or TIR domain-containing adaptor inducing interferon-β (TRIF). These core necroptosis modulating proteins have been comprehensively revealed as potent drivers and suppressors of disease in inbred mouse strains. However, their roles in human disease within the ‘real world’ of diverse genetic backgrounds, natural infection and environmental challenges remains less well understood. Over 20 unique disease-associated human germline gene variants in this core necrotic machinery have been reported in the literature and human clinico-genetics databases like ClinVar to date. In this review, we provide an overview of these human gene variants, with an emphasis on those encoding MLKL. These experiments of nature have the potential to not only enrich our understanding of the basic biology of necroptosis, but offer important population level insights into which clinical indications stand to benefit most from necroptosis-targeted drugs.

Introduction

Programmed cell death takes many forms and is crucial to every aspect of normal animal development and homeostasis. The most well studied programmed cell death pathway is the caspase-dependent apoptosis. Apoptosis can be initiated by a range of intrinsic and extrinsic signals, and is commonly regarded as a ‘clean death’ characterised by the caspase-mediated disassembly of cells into highly phagocytosable, membrane enclosed bundles [1,2]. Unlike apoptosis, necroptosis is a caspase-independent form of programmed cell death that is characterised by the release of highly inflammatory cytokines, intracellular proteins, and nucleic acids into the extracellular space [3–6]. In turn, necroptosis is itself induced by inflammatory cytokines and danger- or pathogen-associated molecular patterns via their cognate transmembrane receptors or intracellular pattern recognition proteins like nucleic acid sensor Z-DNA Binding Protein-1. Of these various initiating stimuli, the most well studied route to necroptosis is downstream of tumour necrosis factor receptor 1 (TNFR1). This signal triggers the eventual formation of the RIPK1 and RIPK3-containing necrosome prior to terminal MLKL activation and cell death (Figure 1) [7–9].

Importantly, several additional, highly context-dependent facets to MLKL function have been reported (recently reviewed by Weir et al. [3]). These include roles in potassium channel mediated promotion of inflammasome activation [10], endocytic and exocytic modulation of cytokine release and membrane repair [11–14], myeloid sheath remodelling [15], neutrophil extracellular trap formation [16,17] and even the direct suppression of intracellular bacteria [18,19].
**Mlkl** gene knock-out and knock-in mutant mice have revealed necroptosis as a driver or protective factor in murine disease spanning every bodily system [20]. Simultaneously, massively parallel sequencing technologies have increased the efficiency and reduced the cost of human genotyping. This has led to the rapid accumulation of human genomic data and even paired phenotypic data in large open access databases like gnomAD [21] and the Global Biobank Engine [22]. Rare mutations in human **MLKL** have revealed neurological and metabolic pathologies where the absence of MLKL function plays a driving role [23–25], whilst rare and *de novo* patient mutations in MLKL signal modulators like **CASP8** and **RIPK1** [26], and common polymorphisms in **MLKL** [27] have provided insight into pathologies where excessive necroptotic signalling is an important contributor to inflammatory disease (Figure 2A). Together these studies of MLKL function in humans reveal some similarities, but also many key differences to observations made in inbred laboratory mouse strains housed under specific pathogen-free conditions [20].

---

**Figure 1.** TNF-induced necroptosis occurs when upstream pro-survival and pro-apoptotic pathways are inhibited.

(A) The binding of TNF to TNFR1 stimulates downstream nuclear factor-κB activation and other pro-survival, proinflammatory signals. (B) When cIAP1/2 activity is low, signalling is diverted to the formation of a death-induced signalling complex termed Complex II (a/b). This physically distinct complex is variably composed of TRADD, FADD, RIPK1, RIPK3 and the apoptosis initiator Caspase-8. (C) Necroptosis is activated when cellular conditions curb Caspase-8 activity and favour the assembly of RIPK1 and RIPK3, via their RIP Homotypic Interaction Motif (RHIM) domains, into a high molecular mass complex termed the necrosome. Here, RIPK3 is activated by autophosphorylation and MLKL is recruited and phosphorylated by RIPK3. MLKL dissociates from RIPK3 and oligomerised MLKL is trafficked to biological membrane [84,85]. The precise molecular events that lead to lytic permeabilization of the cell are still a matter of contention [86]. Sites of some selected published human germline mutations shown to be associated with human disease due to gain (red) or loss/reduction in function (green) are shown.
MLKL truncation/deletion mutations in human neurodegeneration

To date, only four individuals that are homozygous for a predicted loss of function (LOF) MLKL gene variant have been reported in the gnomAD database, a carefully curated collection of whole genome or exome data for over 140,000 human adults of diverse ancestry [21]. In 2020, Faergman et al. reported homozygosity of one of these MLKL variants (p.Asp369GlufsTer22, rs561839347) in two brothers diagnosed with progressive neurodegenerative spectrum disorder [24,28]. MLKL was not detectable by western blot in tissue derived from these patients, and patient-derived fibroblasts did not undergo programmed cell death when exposed to an exogenous necroptotic stimulus in culture. These data support gnomAD’s ‘loss of function’ classification of p.Asp369GlufsTer22, making this the first peer-reviewed, clinical description of humans that are homozygous for an MLKL LOF gene variant. The brothers presented with an asymmetric lower limb weakness at the ages of 19 and 30, respectively, which developed into a novel progressive neurodegenerative disorder characterised by paresis, ataxia and dysarthria. Magnetic resonance imaging performed at 28 and 31 years, respectively, after onset of symptoms revealed severe global cerebral, cerebellar, cortical cerebellar fibers tract and brainstem atrophy and small, discrete periventricular T2-hyperintense white matter lesions. All pathology was limited to the nervous system and the patients did not exhibit any increased susceptibility to infections. It is important to
note that this MLKL mutation also segregated with a homozygous in-frame deletion of one amino acid in the adjacent FA2H gene (fatty acid o-hydroxylase), and a maternally inherited missense amino acid substitution in the X-linked gene API52 (vesicle sorting and transport) in these patients. While FA2H variant function was not impaired when examined in vitro and the API52 variant is classified as 'benign' based on ACMG guidelines [29], the influence of these and other genetic/environmental modifiers cannot be fully excluded from the severe phenotype exhibited by these individuals.

Another MLKL LOF gene variant (p.Gln48Ter, rs763812068) was found to be >20 fold enriched in a cohort of Hong Kong Chinese patients suffering from the neurodegenerative disease Alzheimer’s, relative to a large ancestry-matched population [23]. This MLKL LOF variant is specific to populations of Southern Chinese descent, was only present in heterozygotes, and was not linked to any predicted damaging mutations in the adjacent FA2H gene. Wang et al. reported that shRNA-mediated knock down of MLKL in APPswe-293 cells led to an increased ratio of amyloid beta proteins Aβ42 to Aβ40. Further study of the precise role of MLKL in modulating levels of these proteins in neuronal cells remains an important area of future investigation.

Homozygous and heterozygous Mkl knockout (MklKO/KO) mice do not appear to exhibit the spontaneous, progressive neurodegneration observed in the patients described by Faergeman et al. [24] and Wang et al. [23], implicating the contribution of additional genetic and/or environmental modifiers or key-interspecies differences in MLKL function. MLKL protein is present at low to undetectable levels in the healthy adult mouse brain and spinal cord [30–32], and was reported to be dispensable to the onset and severity of mouse autoimmune lateral sclerosis (ALS) [32]. There are reports however that MLKL is induced following injury to the brain and spinal cord [30–32] and multiple sclerosis [36], and poorer outcomes in models of physical nerve injury [15]. These mouse data, combined with the wide steady state distribution of MLKL essential for neurological function in humans. The collective global frequency of MLKL LOF alleles is 0.0007, (equivalent to 1–2 in every 1000 individuals being heterozygous carriers) (Figure 2B). The identification and clinical description of additional human individuals that are homozygous or compound heterozygous for MLKL LOF alleles will shed further light on whether the absence of MLKL alone is sufficient to give rise to neurodegenerative disease, or if other genetic or environmental events are indeed at play.

**An MLKL missense hypomorph in Maturity Onset Diabetes of the Young (MODY)**

Recently, a heterozygous MLKL missense variant p.G316D (rs375490660) was reported to be associated with Maturity Onset Diabetes of the Young (MODY) in a Palestinian family [25]. This variant segregates with a known MODY-associated LOF gene variant in the gene encoding the pancreatic transcription factor PDX1, and other predicted deleterious variants in the genes ERN2 (endoplasmic reticulum stress), NIPAL4 (Mg2+ transporter activity) and SPTBN4 (actin binding). When compared with exogenously produced MLKLWT, protein levels of exogenously produced MLKL p.G316D are significantly reduced. RIPK3-phosphorylated (Ser358) MLKL p.G316D are basically undetectable despite normal upstream signalling. Exogenous expression of MLKL p.G316D was also unable to reconstitute necrotic cell death in two lineage-distinct CRISPR-Cas9 MLKLKO/KO human cell lines and did not appear to influence the function of endogenously expressed MLKLWT in MLKL wild-type cells (simulating the heterozygous state of patients). While the stability and function of endogenously expressed MLKL p.G316D were not verified in patient-derived cells in its endogenous heterozygous context, normal levels of MLKL p.G316D mRNA in patient derived cells indicates that this missense mutation does not lead to reduced mRNA stability [25]. For this reason, we have chosen to classify this missense variant for the purpose of this review as a 'hypomorph' as opposed to a full LOF variant, as the phospho-Ser358-independent functions of MLKL p.G316D are yet to be investigated.

With a global minor allele frequency of 1.062 × 10⁻⁵, MLKL p.G316D homozygotes have not been recorded in the gnomAD database. How a monoallelic reduction in necrotic cell death contributes to the aetiology of diabetes in this family remains a matter of investigation. MklKO/KO mice do not display any of the hallmarks of diabetes when fed a standard laboratory mouse chow diet, and actually demonstrate improved glucose and insulin tolerance relative to MklWT/WT controls when placed on a high fat diet for more than 12 weeks [38,39]. Investigating whether Mkl gene knockout or mutation is a genetic modifier in mouse models of spontaneous
diabetes (e.g. Pdx1<sup>Wt/KO</sup> mice [40]) could provide a useful route for the mechanistic dissection of these human findings.

Importantly, such studies can also prompt examination of potential risk posed by other human MLKL LOF and missense variants to the incidence of MODY. With no ‘gold standard’ criterion or threshold for diagnosing MODY in human patients, broadening gene panels for precision genetic testing will inform clinical diagnosis and management [41].

**Common MLKL missense variants in inflammatory disease, historically important hypermorphs?**

The biological consequences of spontaneous and rationally designed MLKL gain of function or ‘activating’ mutations have been described both in vitro and in vivo in murine models [30,42,43]. Human MLKL however is less amenable to rationally designed modifications that confer RIPK3 independent activity [43,44]. In 2020, a random, chemically induced germline missense mutation in mouse Mkl was shown to result in systemic lethal neonatal inflammation in homozygotes and hematopoietic dysfunction in heterozygotes [27]. This mutation, Mkl<sup>p.D139V</sup>, confers constitutive cell death activity to MLKL, removing the requirement of upstream necroptotic signalling and RIPK3-mediated phosphorylation. The human equivalent, MLKL<sup>p.D140V</sup>, has been observed only once, and only in heterozygous form in humans in the gnomAD database (rs1330913532).

Interestingly, three very closely situated MLKL missense gene variants are amongst the most prevalent MLKL single nucleotide polymorphisms (SNPs) present in humans. These SNPs, MLKL<sup>p.Ser132Pro</sup>, MLKL<sup>p.Arg146Gln</sup> and MLKL<sup>p.Gly*202Val</sup>, have not been previously associated with human disease in any previous genome-wide- or phenome-wide-association studies (GWAS or PheWAS) individually. They were however shown to occur in trans at 10–12 times the expected frequency in a cohort of patients suffering from chronic recurrent multifocal osteomyelitis (CRMO) [27]. While this association has not been independently replicated in a second CRMO patient cohort to date, this finding does fit nicely with mouse and human studies that implicate ‘unchecked’ necroptosis in the progression of inflammatory diseases [20,26].

An analysis of the cellular function of the protein products of these common human MLKL SNPs relative to wild-type MLKL is yet to be reported in the literature. However, the hypermorphic nature of the closely situated mouse mutation Mkl<sup>p.D139V</sup> does raise important questions as to the evolutionary significance of such high allele frequencies. An estimated 8% of the global population are heterozygous carriers of MLKL<sup>p.S132P</sup>, MLKL<sup>p.R146Q</sup> or MLKL<sup>p.G*202V</sup> based on gnomAD data, and 167 are homozygotes. Many reported hypermorphic variants in immune-related genes that confer a survival advantage to specific pathogens have achieved high allele frequency in certain populations [45,46]. Many such SNPs are also associated with an increased relative risk of autoinflammatory diseases like inflammatory bowel disease and systemic lupus erythematosus [46]. The identification of such evolutionary triads (pathogen - gene hypermorph — inflammatory disease) has the potential to blaze important trails into the development of novel anti-microbials and immunomodulatory therapies alike.

By this same evolutionary logic, MLKL’s implication in diseases like diabetes and Alzheimer’s also warrants the investigation of any historical survival advantage conferred by MLKL gene variants or expression Quantitative Trait Loci (eQTL) with regards to nutrient acquisition and storage. An intriguing example of this was described recently for MLKL’s upstream activator RIPK1. Human gene variants that increase RIPK1 gene expression were found to be associated with obesity [47]. Nutrition and metabolism serve alongside pathogens as major evolutionary drivers of human genetic variation, and are core determinants of the common disorders (e.g. cardiovascular disease), that contribute substantially to disease burden in the modern world [48].

**MLKL gene variants as modifiers of complex polygenic human traits and diseases**

To date, MLKL gene variants have only been weakly associated with human traits or changes in disease risk in conventional GWAS. The highest 'P' value reported for an MLKL variant in a published GWAS was for a non-coding SNP rs2057805 (global MAF 0.2489) located in an upstream regulatory region in adolescent idiopathic scoliosis [49]. This association reached genome wide significance with a Bonferroni-adjusted P-value of 3 × 10<sup>-9</sup>. Other notable associations of MLKL SNPs with quantitative human traits that are significant or approaching genome wide significance include one with comparative height at age 10 (P = 5.26 × 10<sup>-7</sup>) [50] and another
with mean reticulocyte volume, \( P = 1 \times 10^{-8} \) (Global Biobank Engine, Stanford, CA (URL: http://gbe.stanford.edu accessed September 2021)) [22]. Interestingly, three non-coding SNPs in MLKL’s obligate activating kinase RIPK3 are each very strongly associated with standing height in humans, \( P \) values \(< 4 \times 10^{-23} \) [22]. While the small ‘beta’ log odds ratios for each of these MLKL and RIPK3 SNPs described indicate that they account for only very low proportions of the phenotypic variance in these quantitative traits, they nonetheless highlight the potential of such unbiased approaches for uncovering unexpected gene-function links [51].

**Disease causing gene variants identified in important upstream regulators of MLKL**

When considering the pathophysiological impacts of necroptosis, we must not only consider genetic variation in *MLKL* itself, but also variation in genes that can inappropriately unleash, amplify, or even dampen the cellular activity of MLKL. Based on observations of important MLKL regulatory genes gleaned from genetically modified mice [20], we have plotted for the purposes of this review the number of disease associated human mutations reported in ClinVar [52], as accessed in September 2021 (Figure 2A). This tally is strongly dominated by *RIPK1*, *TNFAIP3* (encoding A20) and *CASP8*, where several unique LOF or missense mutations are characterised by autoimmune and lymphoproliferative syndromes [53]. It is important to note however, that the identification of pathogenic gene variants is heavily biased towards those that associated with severe or atypical disease. A higher number of pathogenic *RIPK1*, *TNFAIP3* and *CASP8* mutations in ClinVar does not equate to a larger contribution to the heritable variation in disease risk, when considering all disease burden in the human population. In fact, it is likely quite the opposite. Examining the mutational spectrum of \(~141,000\) individuals catalogued by the gnomAD database permits a simple visualisation of the high evolutionary constraint on LOF variation in *RIPK1*, *TNFAIP3* and *CASP8* [54] (Figure 2B). *MLKL* and *ZBP1* each exhibit a higher summed frequency of predicted LOF alleles than *RIPK1*, *TNFAIP3* and *CASP8* combined, and both are dotted with a larger repertoire of more common (>MAF 0.001) missense gene variants (Figure 2C). The higher missense and LOF variation tolerance profiles of *MLKL*, *RIPK3* and *ZBP1* indicate that gene variants are less likely to result in a loss of reproductive fitness (e.g. severe disease in children and young adults) that would cause them to be subject to purifying selection over time [55]. By this same logic however, the higher levels of standing protein-coding variation in *MLKL*, *RIPK3* and *ZBP1* genes also increases the statistical likelihood that these genes can act as low effect size modifiers of polygenic traits in humans (e.g. disease risk, infection response, height or weight) [56].

**MLKL and the varied manifestations of inborn errors in CASP8**

A full decade before MLKL’s role in cell death was discovered, inherited deficiency of Caspase 8 was reported to mediate autoimmune lymphoproliferative syndrome (ALPS). Chun et al. [57] reported homozygosity of a CASP8 variant (p.R248W) in two siblings that presented with lymphadenopathy and splenomegaly. Caspase-8 p.R248W exhibited reduced stability and resulted in an enzymatically inactive protein, with peripheral blood lymphocytes defective in CD95-induced apoptosis. Caspase-8 activity is an important determinant of programmed cell death downstream of death receptor and inflammasome activation [58]. The absence or inhibition of Caspase-8 or c-FLIP\(_L\) activity facilitates the stabilisation of RIPK1 and RIPK3 [59–62] (both shown to be cleaved by Caspase-8 and/or Caspase-8-c-FLIP\(_L\) heterodimers). Amongst other signalling events, this also promotes the formation of the necroosome and MLKL-mediated cell death. Mice deficient in Caspase 8 die at embryonic day 10.5 but *Casp8\(^{WT/KO}\)* heterozygotes are phenotypically normal [63]. *Casp8\(^{KO/KO}\)* embryonic lethality does not occur on a *Mlkl\(^{KO/KO}\)* background, but *Casp8\(^{KO/KO}\)*, *Mlkl\(^{KO/KO}\)* mice do go on to develop progressive lymphadenopathy [64]. In light of this later observation, dysregulated MLKL function and necrototic cell death is likely to be more pertinent to the many examples of human CASP8 variant -borne disease that do not manifest as ALPS.

Caspase-8 deficiency manifests as very early-onset Inflammatory Bowel Disease (VEO-IBD) in some individuals. Lehle et al. [65] reported three unrelated patients with homozygous CASP8 mutations (p.Q237R and p.R265W (equivalent position to canonical isoform R248W)) that presented with diarrheal, perianal disease, failure to thrive and discontinuous severe proctocolitis, as well as increased susceptibility to bacterial and viral infections. Primary patient cells and cells engineered to express CASP8 p.Q237R exogenously exhibited...
increased IL-1β release in response to lipopolysaccharide (LPS) priming, that could be blocked by NLRP3-mediated inflammasome inhibitor MCC950 and the MLKL inhibitor necrosulfonamide. Furthermore, CASP8 p.Q237R, but not p.R265W, was also shown to predispose engineered HT-29 colon carcinoma cells to increased MLKL oligomerisation and death when exposed to a necroptotic stimulus [65]. The important role of MLKL in this disease scenario is further supported by recent observations that MLKL fully mediates the ileitis and colitis observed in mice with intestinal epithelial cell-specific deficiency of Caspase-8 [66]. Chun et al.’s [65] and Lehle et al.’s [67] clinical descriptions of distinct disease manifestation in individuals harbouring CASP8 p.R248W/R265W also highlights that unchecked necroptosis may be variably expressed as a phenotype of the same CASP8 mutation, depending on the individual. The genetic or environmental determinants of this disparate role of MLKL remains an important line of future investigation into the potential toxicity of Caspase-8 targeted drugs.

Choose your battle: MLKL and disease associated with inborn errors of RIPK1

Given the important position of RIPK1 at the nexus of several cellular signalling pathways, MLKL and necroptosis account for a significant portion, but not all of, the downstream effects born of genetically encoded RIPK1 dysfunction. In 2018, Cuchet-Lourenco et al. [68] reported four individuals that were homozygous for three unique RIPK1 LOF nucleotide deletions, and a number of additional patients with homozygous RIPK1 LOF alleles were reported soon after [69]. Patients presented with early-onset inflammatory bowel disease, lymphopenia and arthritis of varying severity. One patient also suffered from growth restriction, severe motor delay and mild intellectual disability [70]. An increased susceptibility to viral, bacterial and fungal infection was also reported [53,71]. Patient fibroblasts isolated from one of these patients were shown to be more susceptible to cell death in the presence of TNF and poly(I:C). These cells were protected from death by the MLKL inhibitor necrosulfonamide, strongly implicating necroptosis [68]. Similarly to Casp8, Ripk1 knockout in murine models is homozygous lethal, with mice dying during the immediate post-natal period due to systemic inflammation and cell death in multiple tissues. This inflammation is ameliorated in a MlklKO/KO background, but mouse pup survival is only extended by a few days [72]. The severe phenotype of RIPK1 KO/KO mice is only bypassed when both necroptosis and extrinsic apoptosis are removed from the equation by compound genetic crosses [72–74]. Homozygous RIPK1 LOF in humans can lead to severe disease, but is not incompatible with life as it is in mice. Is this difference intrinsic to inter-species differences in RIPK1 itself, or can it be explained by key species-specific differences in the regulation of downstream signal effectors like MLKL?

Compounding these questions are disease causing missense RIPK1 gene variants that prevent RIPK1 cleavage by caspases. Heterozygosity of such ‘cleavage resistant’ alleles is sufficient to induce a severe periodic inflammatory syndrome in humans characterised by fever and lymphadenopathy [75–77]. Homozygosity reduces the lifespan of mouse embryos to E10.5, well shorter than that observed for Ripk1KO/KO mice and for reasons that cannot be remedied by the deletion of Mlkl [76,78]. The hyperinflammatory phenotype of heterozygous adult mice is similarly unaltered by the genetic deletion of Mlkl (N. Lalaoui, unpublished).

RIPK3 variants in human health and disease

To date, there have been no clinical descriptions of humans that are homozygous for RIPK3 LOF gene variants. One individual that is homozygous for a predicted LOF RIPK3 allele was recorded as part of the ‘human knockout project’, though details of this individual’s phenotype were not provided [79]. The allele in question, RIPK3 p.Pro493ThrfsTer9 (rs531266348), contains a frame shift insertion that may lead to a short C terminal truncation as opposed to a full LOF. As such, its classification as ‘Loss of Function’ is classified as low confidence in the gnomAD database, as is the only other potential LOF variant found in homozygous form; RIPK3 p.Arg422Ter (rs146886719). Similar to the Mlk1KO/KO mouse, Ripk3KO/KO mice do not show any overt signs of spontaneous neurodegenerative disease or diabetes under steady state conditions, even when aged beyond 12 months [80,81]. Interestingly, Ripk3KO/KO mice do show evidence of disturbed bone architecture and increased osteoclasts, supporting the reported association of the RIPK3 cis-eQTL rs3212240 with lower estimated bone mineral density in a human cohort [82]. Given our discussion of gene variation and evolutionary fitness, it would be remiss not to mention reports that Mlk1KO/KO and Ripk3KO/KO mice show a significantly reduced propensity for reproductive organ aging [81,83]. Necroptosis deficient mice sire more pups at advanced age than...
their wild-type counterparts. This advantage is offset by the reduced fitness of the pups born to older fathers, but certainly warrants consideration of the influence of necroptosis gene variation and necroptosis drugs in human fertility going forward [81].

Conclusion
This review gives an overview of the current landscape of MLKL’s role in heritable disease. Two distinct, de novo MLKL LOF variants have been shown to segregate with a severe familial neurodegenerative disorder and familial maturity onset diabetes of the young (MODY). While MLKL LOF alleles are more prevalent in the population relative to other key genes involved in programmed cell death, they are dwarfed in frequency (>100-fold less frequent) by a series of common non-conservative protein modifying mutations that cluster at key functional domains of MLKL. The identification and clinical description of additional families and individuals carrying homozygous and heterozygous MLKL LOF gene variants is not unlikely given the growing uptake of whole genome sequencing for clinical diagnosis. While rare, these individuals will reveal new and important insights into the role of MLKL and disease aetiology and the basic molecular mechanism of MLKL’s varied cellular functions. They will help to focus and fine-tune the study of the trait- and disease-modifying potential of the MLKL protein coding variants carried by >10% of the global population, unlocking new clinical indications and contraindications for drugs that target necroptosis and its important upstream regulators.

Perspectives
- Naturally occurring human gene variants are important tools for the study of necroptosis at the molecular and pathophysiological level.
- Rare and de novo necroptosis gene variants have been implicated in autoinflammatory disease, neurodegeneration and metabolic disease.
- More than 10% of individuals carry protein-coding single nucleotide polymorphisms in MLKL. Studying their role in human health and disease will uncover new clinical indications and contraindications for drugs that target necroptosis and its important upstream regulators.

Competing Interests
S.E.G. and J.M.H. contribute to a project developing necroptosis inhibitors in collaboration with Anaxis Pty Ltd.

Funding
J.M.H. is the recipient of an Australian NHMRC Career Development Fellowship 1142669 and Ideas Grant 2011584. S.E.G. is the recipient of The Wendy Dowsett Scholarship and an Australian Government Research Training Program Stipend Scholarship. We also thanks the Victorian Government Operational Infrastructure Support scheme.

Author Contributions
S.E.G. and J.M.H. performed analyses of publicly available human gene variant frequencies, conceived, constructed figures for and wrote this manuscript.

Acknowledgements
We wish to thank Michael S. Hildebrand for his careful reading of this manuscript and helpful suggestions and James M. Murphy for generously providing the graphical elements used in Figure 1. Due to length restrictions, we have cited recent long-form reviews in place of some relevant primary sources.

Abbreviations
ALPS, autoimmune lymphoproliferative syndrome; CRMO, chronic recurrent multifocal osteomyelitis; GWAS, Genome Wide Association Studies; LOF, loss of function; MLKL, mixed lineage kinase domain-like; MODY,
Maturity Onset Diabetes of the Young; RIPK1, receptor interacting protein kinase 1; SNPs, single nucleotide polymorphisms; TNFR1, tumour necrosis factor receptor 1; ZBP1, Z-DNA Binding Protein-1.

References

1 Kolb, J.P., Ougrin, Ill., T.H., Oberst, A. and Martinez, J. (2017) Programmed cell death and inflammation: winter is coming. Trends Immunol. 38, 705–718 https://doi.org/10.1016/j.it.2017.06.009

2 Boada-Romero, E., Martinez, J., Heckmann, B.L. and Green, D.R. (2020) The clearance of dead cells by efferocytosis. Nat. Rev. Mol. Cell Biol. 21, 398–414 https://doi.org/10.1038/s41580-020-0232-1

3 Weir, A., Hughes, S., Rashidi, M., Hildebrand, J.M. and Vince, J.E. (2021) Necrototic mixers and shakers: cell types, inflammatory drivers and diseases. Curr. Opin. Immunol. 68, 83–97 https://doi.org/10.1016/j.coi.2020.09.008

4 Tanzer, M.C., Frauenstein, A., Stafford, C.A., Phulphagar, K., Mann, M. and Meissner, F. (2020) Quantitative and dynamic catalogs of proteins released during apoptotic and necrotic cell death. Cell Rep. 30, 1260–1270.65 https://doi.org/10.1016/j.celrep.2019.12.079

5 Shlomovitz, I., Erlich, Z., Arad, G., Edry-Botzer, L., Zargarian, S., Cohen, H. et al. (2021) Proteomic analysis of necroptotic extracellular vesicles. Cell Death Dis. 12, 1059 https://doi.org/10.1038/s41419-021-04317-z

6 Murali, S., Yamaguchi, Y., Shirasaki, Y., Yamagishi, M., Shindo, R., Hildebrand, J.M. et al. (2019) A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs. Nat. Commun. 9, 4457 https://doi.org/10.1038/s41467-018-06985-6

7 Samson, A.L., Garnish, S.E., Hildebrand, J.M. and Murphy, J.M. (2021) Location, location, location: a compartmentalized view of TNF-induced necrototic signaling. Sci. Signal. 14, eaab6178 https://doi.org/10.1126/scisignal.abc1178

8 Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liu, D. et al. (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 https://doi.org/10.1016/j.cell.2011.11.031

9 Zhoa, J., Necroptosis in diabetes. Cell Death Dis. 12, 345 https://doi.org/10.1038/cddis.2012.34

10 Kolb, J.P., Oguin, III, T.H., Oberst, A. and Martinez, J. (2017) Programmed cell death and inflammation: winter is coming. Trends Immunol. 38, 705–718 https://doi.org/10.1016/j.it.2017.06.009

11 Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T. et al. (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 464–472 https://doi.org/10.1038/nature19057

12 McInnes, G., Tanigawa, Y., DeBoever, C., Lavertu, A., Olivieri, J.E., Aguirre, M. et al. (2019) Global Biobank Engine: enabling genotype-phenotype discovery. Cell Death Dis. 11, 300.e1 https://doi.org/10.1038/s41419-020-2494-0

13 Faergeman, S.L., Evans, H., Atfield, K.E., Desei, C., Kuttikatte, S.B., Sommerlund, M. et al. (2020) A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis. 11, 303 https://doi.org/10.1038/s41419-020-2494-0

14 Fan, W., Guo, J., Gao, B., Zhang, W., Ling, L., Xu, T. et al. (2019) Flotillin-mediated endocytosis and ALX-syntenin-1-mediated exocytosis protect the cell membrane from damage caused by necroptosis. Sci. Signal. 12, eaau3423 https://doi.org/10.1126/scisignal.aau3423

15 Ying, Z., Pan, C., Shao, T., Liu, L., Guo, D. et al. (2018) Mixed lineage kinase domain-like protein MLK3 breaks down myelin following nerve injury. Mol. Cell 72, 457–468.e5 https://doi.org/10.1016/j.molcel.2018.09.011

16 Speir, M., Djajawi, T.M., Conos, S.A., Tye, H. and Lawlor, K.E. (2021) Targeting RIP kinases in chronic in

17 Zargarian, S., Shlomovitz, I., Erlich, Z., Hourizadeh, A., O

18 Sai, K., Parsons, C., House, J.S., Kathariou, S. and Ninomiya-Tsuji, J. (2019) Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria formation in necroptotic neutrophils. Mol. Cell 72, 414 https://doi.org/10.1016/j.molcel.2019.01.001

19 Faergeman, S.L., Evans, H., Atfield, K.E., Desei, C., Kuttikatte, S.B., Sommerlund, M. et al. (2020) A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis. 11, 300.e1 https://doi.org/10.1038/s41419-020-2494-0

20 Tovey Crutchfield, E.C., Gamish, S.E. and Hildebrand, J.M. (2021) The role of the key effector of necroptotic cell death, MLKL, in mouse models of disease. Biomolecules 11, 803 https://doi.org/10.3390/biom11060803

21 Cordero, P., Mancini, E., Fraternali, C., Manca, V., Monaco, M.P. et al. (2020) A transgenic model of age-dependent myeloperoxidase-induced inflammation: winter is coming. Trends Immunol. 35, 2295–2297 https://doi.org/10.1016/j.it.2020.03.006

22 Feagernan, S.L., Evans, H., Atfield, K.E., Desei, C., Kuttikatte, S.B., Sommerlund, M. et al. (2020) A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis. 11, 303 https://doi.org/10.1038/s41419-020-2494-0

23 Wang, B., Bao, S., Zhang, C., Zhou, X., Wang, J., Fan, Y. et al. (2018) A rare variant in MLKL confers susceptibility to ApoE varepsilon4-negative Alzheimer’s disease in Hong Kong Chinese population. Neurobiol. Aging 68, 160.e1–160.e7 https://doi.org/10.1016/j.neurobiolaging.2018.03.006

24 Faergeman, S.L., Evans, H., Atfield, K.E., Desei, C., Kuttikatte, S.B., Sommerlund, M. et al. (2020) A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death Dis. 11, 303 https://doi.org/10.1038/s41419-020-2494-0

25 Hildebrand, J.M., Lo, B., Tomel, S., Mattel, V., Young, S.N., Fitzgibbon, C. et al. (2021) A family harboring an MLKL loss of function variant implicates necroptosis in diabetes. Cell Metab. 34, 724 https://doi.org/10.1016/j.cmet.2021-03-0673

26 McInnes, G., Tanigawa, Y., DeBoever, C., Lavertu, A., Olivieri, J.E., Aguirre, M. et al. (2019) Global Biobank Engine: enabling genotype-phenotype discovery. Cell Death Dis. 11, 300.e1 https://doi.org/10.1038/s41419-020-05066-5

27 Hildebrand, J.M., Kauppi, M., Majewski, I.J., Liu, Z., Cox, A.J., Miyake, S. et al. (2020) A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nat. Commun. 11, 3150 https://doi.org/10.1038/s41467-020-16819-2

28 Taylor, J.C., Martin, H.C., Lise, S., Brokhorne, J., Cazier, J.B., Rimmer, A. et al. (2015) Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat. Genet. 47, 717–726 https://doi.org/10.1038/ng.3304

29 Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J. et al. (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet. Med. 17, 405–424 https://doi.org/10.1038/gim.2015.30
